

amfAR

MAKING AIDS HISTORY


amfAR-UCSF HIV Cure Trial

Rationale: Immunotherapy in NHPs

nature

Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys

Erica N. Borducchi¹, Crystal Cabral¹, Kathryn E. Stephenson¹, Jinyan Liu¹, Peter Abbink¹, David Ng'ang'a¹, Joseph P. Nkolola¹, Amanda L. Brinkman¹, Lauren Peter¹, Benjamin C. Lee¹, Jessica Jimenez¹, David Jetton¹, Jade Mondesir¹, Shanell Mojta¹, Abishek Chandrashekar¹, Katherine Molloy¹, Galit Alter², Jeffrey M. Gerold³, Alison L. Hill³, Mark G. Lewis⁴, Maria G. Pau⁵, Hanneke Schuitemaker⁵, Joseph Hesselgesser⁶, Romas Geleziunas⁶, Jerome H. Kim^{7†}, Merlin L. Robb⁷, Nelson L. Michael⁷ & Dan H. Barouch^{1,2*}



**Conserved
element vaccine**




**Vaccine
adjuvant**

nature

Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys

Erica N. Borducchi^{1,6}, Jinyan Liu^{1,6}, Joseph P. Nkolola^{1,6}, Anthony M. Cadena^{1,6}, Wen-Han Yu², Stephanie Fischinger², Thomas Broge², Peter Abbink¹, Noe B. Mercado¹, Abishek Chandrashekar¹, David Jetton¹, Lauren Peter¹, Katherine McMahan¹, Edward T. Moseley¹, Elena Bekerman³, Joseph Hesselgesser³, Wenjun Li⁴, Mark G. Lewis⁵, Galit Alter², Romas Geleziunas³ & Dan H. Barouch^{1,2*}



bNAbs




TLR Agonist


nature

Early antibody therapy can induce long-lasting immunity to SHIV

Yoshiaki Nishimura¹, Rajeev Gautam¹, Tae-Wook Chun², Reza Sadjadpour¹, Kathryn E. Foulds³, Masashi Shingai¹, Florian Klein^{4,5}, Anna Gazumyan⁶, Jovana Golijanin⁶, Mitzi Donaldson³, Olivia K. Donau¹, Ronald J. Plishka¹, Alicia Buckler-White¹, Michael S. Seaman⁷, Jeffrey D. Lifson⁸, Richard A. Koup³, Anthony S. Fauci², Michel C. Nussenzweig^{6,9} & Malcolm A. Martin¹




bNAbs



HIV viremia

Clinical Trial Schematic

Weeks 0, 4, 12




**Conserved
element vaccine
via
electroporation**

Week 20




MVA boost

Week 24




**bNAbs
10-1074
VRC07-523LS**

Weeks 25-33




**TLR9 Agonist
Lefitolimod**

Week 34



**bNAbs
10-1074
VRC07-523LS**

Weeks 34-80



**Analytic
treatment
interruption
(Set-point)**

Study ongoing ... no results to report yet

amfAR Institute
FOR HIV CURE RESEARCH




MOLOGEN AG
THE POWER OF IMMUNOTHERAPIES



Dale and Betty Bumpers
VACCINE RESEARCH CENTER
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Department of Health and Human Services

Study Opened: February 20, 2020



Incredibly dedicated study volunteers

Study volunteers

11

Study visits

505

(as of July 25, 2022)

JAWS

amfAR
MAKING AIDS HISTORY



“We’re gonna need a bigger boat”



Tom Perrault
Angela Decenzo

FEATURES

My HIV Cure Trial

In this essay, Tom Perrault recounts his journey toward hopefully controlling HIV without medication.

June 27, 2022 • By Tom Perrault